ADMA Biologics Inc (NASDAQ:ADMA) Shares Bought by Calamos Advisors LLC

Calamos Advisors LLC raised its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 25.3% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 533,837 shares of the biotechnology company's stock after purchasing an additional 107,931 shares during the period. Calamos Advisors LLC owned 0.22% of ADMA Biologics worth $10,591,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. D.A. Davidson & CO. raised its holdings in shares of ADMA Biologics by 110.5% during the 1st quarter. D.A. Davidson & CO. now owns 24,760 shares of the biotechnology company's stock worth $491,000 after acquiring an additional 13,000 shares during the period. Principal Financial Group Inc. raised its holdings in shares of ADMA Biologics by 2.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,288,121 shares of the biotechnology company's stock worth $25,556,000 after acquiring an additional 29,107 shares during the period. New York State Teachers Retirement System raised its holdings in shares of ADMA Biologics by 96.2% during the 1st quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock worth $4,402,000 after acquiring an additional 108,800 shares during the period. KBC Group NV raised its holdings in shares of ADMA Biologics by 11.5% during the 1st quarter. KBC Group NV now owns 11,217 shares of the biotechnology company's stock worth $223,000 after acquiring an additional 1,154 shares during the period. Finally, Lisanti Capital Growth LLC raised its holdings in shares of ADMA Biologics by 75.8% during the 1st quarter. Lisanti Capital Growth LLC now owns 308,440 shares of the biotechnology company's stock worth $6,119,000 after acquiring an additional 132,970 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Down 1.6%

ADMA traded down $0.28 on Monday, hitting $18.00. The company had a trading volume of 776,501 shares, compared to its average volume of 3,697,058. The firm has a market cap of $4.30 billion, a P/E ratio of 21.18 and a beta of 0.43. ADMA Biologics Inc has a 1 year low of $10.21 and a 1 year high of $25.67. The company's fifty day moving average price is $20.24 and its 200 day moving average price is $18.73. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The business's revenue was up 40.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.08 earnings per share. As a group, equities analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other news, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director directly owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lawrence P. Guiheen sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the sale, the director directly owned 94,830 shares in the company, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 464,621 shares of company stock valued at $9,644,269 in the last three months. 3.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ADMA. Raymond James Financial lifted their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.